批转市计委拟订的《天津市汽车更新办法》
作者:法律资料网 时间:2024-07-05 05:49:20 浏览:9954
来源:法律资料网
下载地址: 点击此处下载
批转市计委拟订的《天津市汽车更新办法》
批转市计委拟订的《天津市汽车更新办法》
天津市政府
各区、县人民政府，各委、局，各直属单位：
市人民政府同意市计委拟订的《天津市汽车更新办法》。现转发给你们，望认真贯彻执行。
天津市汽车更新办法
汽车的更新改造，是国民经济技术改造的重要内容之一，也是节约能源的一项重要措施。根据《国务院转发关于更新改造老旧汽车的通知》精神和“天津市载重汽车更新试行办法”的执行情况，制定《天津市汽车更新办法》如下：
一、汽车更新范围和标准
从提高效能和降低油耗出发，对社会上拥有的各种载重汽车、军用越野车、小轿车、大中型客车以及各种类型的专用汽车（包括救护车、消防车、工程车、邮政车、冷藏车、油槽车等），凡属下列范围的均应更新。
1．经检修或改换零部件后，在正常路面条件下行驶，耗油量高于下列指标的各种汽车：
汽车类型 代表车型 百公里油耗（升）
八吨载重车 ＪＮ150 24（柴油）
五吨载重车 Ｅａ140 28
四吨载重车 ＣＡ10 29
二吨半至三吨载重车 ＮＪ130 20
二吨载重车 ＢＪ130 17
四轮驱动越野车 ＢＪ212 17
二轮驱动越野车 ＢＪ212Ｂ 15
小 轿 车 ＳＨ760Ａ 14
大中型客车和各类专用车辆按所采用的底盘比照执行。
2．已行驶五十万公里或已经过三次大修的。
3．因各种原因造成车辆严重损坏，无修复价值，或虽能修复，但一次修理费用预计达到新车出厂价百分之五十以上的。
4．车型老旧并已使用多年的进口汽车，国内无配件供应来源，又不宜修复或进行技术改造的。
5．技术状况低劣，不堪使用，无法修复或没有修复价值的。
军队的汽车更新，按照总后勤部的有关规定办理。
二、更新汽车的技术鉴定
更新汽车的技术鉴定工作，由天津市公安局统一组织实施，统一印发“更新汽车技术鉴定表”（简称八联单）。
三、旧车回收
经天津市公安局鉴定淘汰报废的汽车，一律交市物资回收公司经营部门收购，并由回收部门出具收购旧车凭证，据以批供新车。回收部门对收购的旧车，必须解体，一律按废钢铁回收作价办法计算。已回收的旧车不准再转卖，也不得用旧零部件再拼装整车变卖。
更新单位交售旧车时，发动机、变速机、前桥、后桥、车身、车架等总成要基本保持完整，不得随意拆留。交通运输部门和拥有百辆以上车辆的大型车队更新车辆时，除车身、车架必须交售外，其它有修复价值的零部件可酌情拆留自用。
四、新车分配和供应
用于更新的汽车，原则上采用国产汽车，由用户择优选定车型，持“更新汽车技术鉴定表”和交售旧车凭证向下列单位办理新车批供手续：
1．大客车由市建委负责批供；
2．救护车由市卫生局负责批供；
3．消防车由市公安局负责批供；
4．邮政车由市邮电管理局负责批供；
5．火葬车由市民政局负责批供；
6．散装水泥车由市散装水泥办公室负责批供；
7．载重汽车及其它改装车由市物资局负责批供；
8．小汽车（包括小轿车、吉普车、旅行车、工具车和载货量一吨以下的双排座两用车）由市计委负责批供，并按社会集团购买力审批程序办理准购手续。
批供部门要按更新车辆单位提出的车型进行安排。安排不了的，更新车辆单位已找到资源的，经批供部门同意可自购。
根据现行物资分配管理办法，中央直属、直供单位和各地区驻津单位所需要的更新汽车采取划转指标或直接供货办法，由各批供部门办理批供新车手续。
五、更新汽车所需资金来源
1．企业留用的折旧费；
2．企业留用的各种形式的利润留成；
3．企业的大修理基金；
4．行政事业单位可在包干经费内或经费包干结余中开支。
如上述资金仍不够购买新车时，可持已办妥批供新车的“更新汽车技术鉴定表”（第五联），向当地开户人民银行申请中短期设备贷款。用以后年度的上述几项资金归还。归还期最长不得超过三年。
六、更新汽车必须按计划执行
从现在起，更新汽车要逐步编制计划。各主管委、局，按分工管理的不同车种，组织各区、县、局由下至上编制汽车更新计划，经与资源平衡后下达并送市计委备案。
七、更新汽车应注意的几个问题
1．更新汽车要与封存汽车结合起来，凡已经封存，其耗油量高于本办法第一条标准的车辆，不得再启封使用。对已经封存，但不属于报废范围和报废标准的车辆，可启封用于更新。具体工作由市社会车辆管理办公室负责。
2．更新汽车要与车辆总检工作结合起来，凡总检不合格或没经总检的车辆，一律不得再行驶。
3．对已列入更新计划并落实了资金来源，仍逾期不办理报废手续的，要停止供油，吊销牌照。具体工作由各主管委、局会同公安局、石油公司、物资回收公司办理。
八、本办法自批准之日起执行。
1982年7月25日
下载地址: 点击此处下载
关于印发《新疆维吾尔自治区关于大力发展劳务派遣组织推动劳务输出（入）暂行办法》的通知
新政办发〔2006〕130号
关于印发《新疆维吾尔自治区关于大力发展劳务派遣组织推动劳务输出（入）暂行办法》的通知
伊犁哈萨克自治州，各州、市、县（市）人民政府，各行政公署，自治区人民政府各部门、各直属机构：
《新疆维吾尔自治区关于大力发展劳务派遣组织积极推动劳务输出（入）暂行办法》已经自治区十届人民政府第28次常务会议研究同意，现印发你们，请认真贯彻执行。
二○○六年九月五日
新疆维吾尔自治区关于大力发展劳务派遣
组织积极推动劳务输出（入）暂行办法
一、劳务派遣组织的性质和作用
（一）劳务派遣组织是将有就业愿望并符合就业条件的劳动者组织起来，为各类企业、机关事业单位、公益性社会组织提供劳务派遣服务的服务性企业，是市场经济条件下配置人力资源的一种载体，主要经营人力资本，其社会功能为集“培训、就业、维权”于一体，并按“企业化经营，市场化运作，规范化管理”的方式运作。
（二）发展劳务派遣组织，推动劳务输出，对拓宽就业渠道，加快城乡劳动者就业由“自发无序”向“依法有序”转变，创新就业观念和就业服务方式，提高就业的组织化程度和稳定性，切实维护从业者的合法权益，促进下岗失业人员、城镇新增劳动力、大中专毕业生以及农村劳动力转移就业，具有重要作用。
二、劳务派遣组织的运行形式
（三）劳务派遣组织既可从事劳务派遣，也可从事劳务输出，实行投资主体多元化，可以采取国有、集体、个体、私营等多种经济类型和公司制、合伙制、个人独资、股份合作制等多种组织形式。
（四）各类职业中介机构可开办劳务派遣组织。其中，公共就业服务机构开办的劳务派遣组织要事企分开，自主经营，自负盈亏。
国有企业再就业服务中心可转型为劳务派遣组织。
街道（乡镇）、社区等劳动保障事务所和自然人都可组建劳务派遣组织。
（五）向工商行政管理部门申办劳务派遣组织，应持有劳动保障部门核发的从事劳务派遣活动的《资质证书》；注册资本不得低于10万元人民币。
（六）劳务派遣组织可以跨地区、跨所有制、跨行业开展劳务派遣和劳务输出；开展省际间劳务合作和派遣；经依法批准登记后，可开展境外（国外）劳务派遣和劳务输出工作。
（七）各地要发挥劳动力市场在就业信息引导和就业服务方面对劳务派遣或劳务输出工作的作用，推进劳动力市场与劳务派遣组织间信息的联络与沟通。
三、劳务派遣组织和劳务输出工作的管理
（八）劳动关系和劳务协议。
1.劳务派遣组织依法与被派遣人员签订劳动合同，建立劳动关系，明确双方的权利和义务。被派遣人员按劳动合同到用工单位服务。劳动合同的期限和终止由劳务派遣组织与被派遣人员依法约定。
2.劳务派遣组织依法与接受被派遣人员的用工单位（以下称实际用人单位）签订派遣协议，明确双方的权利和义务。协议应对劳务派遣人员的工作内容、岗位要求、工作时间、工资支付（包括支付标准、形式、时间）、社会保险、福利待遇、劳动保护、劳动条件以及管理费收取标准、技能培训等事项依法作出约定。
3.劳务派遣组织开展劳务输出，与输入单位签订劳务协议，其被输出的人员与输入单位签订劳动合同，明确双方的权利和义务。
（九）被派遣人员和劳务输出人员的技能培训。
1.劳务派遣组织要充分利用各类培训机构资源，发挥社会化技能培训的作用，逐步形成与劳务派遣、劳务输出工作紧密联系的社会化培训基地和网络，加强对被派遣人员和劳务输出人员的技能培训，不断提高被派遣人员和劳务输出人员的素质。
2.劳务派遣组织要根据被派遣人员和劳务输出人员多层次、多形式、多样化的就业特点，结合职业教育、技能培训的改革创新，按照产业发展需要，积极采取“订单”、“定向”等灵活方式培训被派遣人员和劳务输出人员，并做好熟练工和各类专业技术人才的预测、培训和储备等工作，努力打造有特色、有影响力的技能培训品牌。
3.劳务派遣组织安排劳务派遣人员、劳务输出人员从事国家规定的技术工种的劳动，其被派遣人员和劳务输出人员必须持有相应的职业资格证书，方可上岗工作。
（十）被派遣人员和劳务输出人员的工资支付和社会保险费的缴纳。
1.被派遣人员的工资支付和社会保险费的缴纳
(1)劳务派遣人员的工资和社会保险费，由实际用人单位承担，一般由劳务派遣组织按月足额发放和缴纳，也可以在派遣协议中约定，由实际用人单位代为支付和缴纳。
劳务派遣组织按规定收取用人单位的管理费后，不得再向被派遣人员收取管理费，或以收取管理费名义克扣劳务派遣人员的工资。
(2)劳务派遣人员的工资、社会保险标准不得低于实际用人单位同岗位职工标准。
对按日支付工资且连续工作满一个月及其以上，或按日支付工资累计工作日满一个月（不含节假日）的劳务派遣人员，用人单位应按本人工资收入为其缴纳社会保险费；本人工资收入低于社会平均工资的，可按社会平均工资的60%为其缴纳社会保险费。
2.劳务输出人员的工资由劳务输入单位支付。
（十一）被派遣人员和劳务输出人员的社会保障。
1.劳务派遣组织和劳务输入单位应依法参加社会保险，按规定为劳务派遣人员和劳务输入人员缴纳社会保险费。其中，被派遣人员或劳务输入人员为农民工的，应优先为其参加工伤和住院医疗保险社会统筹，按规定缴纳工伤和住院医疗保险社会统筹费。
2.劳务派遣人员发生工伤事故，实际用人单位应当协助劳务派遣组织按规定做好工伤申报认定工作，并依法承担其它应支付的工伤人员待遇费用。
劳务输出人员发生工伤事故，由劳务输入单位依法承担工伤保险责任。
（十二）被派遣人员的党、团、工关系及档案管理。
1.劳务派遣人员的党、团、工会组织关系应在劳务派遣组织。被派遣人员的派遣期限超过3个月的，其党、团、工会组织关系可临时转至实际用人单位，参加实际用人单位的党、团、工组织活动。
2.劳务派遣人员的档案由劳务派遣组织统一进行规范管理。
（十三）劳务派遣实行资质管理。
劳动保障部门对劳务派遣组织实施行业资质管理，评定行业资质等级标准。劳务派遣组织按评定的行业资质等级标准，收取劳务派遣管理费。
四、相关扶持政策
（十四）为促进劳务派遣组织发展，对各级公共就业服务机构及街道和有条件的镇劳动保障事务所创办劳务派遣组织，给予不超过10万元的资金支持，所需经费从就业再就业经费中列支。
（十五）劳务派遣组织从实际用人单位收取的全部劳务派遣收入，除缴纳收取的管理费所得税外，其它各项费用包括工资、社会保险等项费用，由实际用人单位在税前列支。
（十六）劳务派遣组织在促进就业再就业方面成绩突出的，各地可给予奖励，所需经费从就业再就业经费中解决。
（十七）劳务派遣组织组织被派遣人员、劳务输出人员开展职业技能培训并成功派遣或输出劳务的，按有关规定享受职业培训、职业介绍补贴。
（十八）劳务派遣组织吸纳下岗失业人员、大中专毕业生等各类人员就业、再就业，按规定享受社会保险补贴、贷款贴息及税费减免各项优惠政策。
五、劳务派遣组织和劳务输出工作的领导与监管
（十九）各级政府要高度重视劳务派遣组织建设和劳务输出工作，切实加强组织领导，主要领导要亲自抓发展、抓规划、抓示范、创品牌。要提升劳务派遣和劳务输出的规模和质量，充分发挥劳务派遣组织、各类职业中介机构在开展劳务派遣和劳务输出工作中的重要作用，促进劳动力资源的合理有效配置，加快贫困地区农村富余劳动力通过转移就业脱贫致富。
（二十）劳动保障部门要加强对劳务派遣组织和实际用人单位执行劳动保障法律法规情况的监督检查，切实维护劳务派遣、劳务输出各方的合法权益，及时制止和纠正违反有关法律、法规的行为。
劳务派遣组织和实际用人单位要遵守劳动和社会保障等法律、法规，认真履行法定义务，依法维护职工的合法权益。被派遣人员和劳务输出人员要履行劳动合同，遵守规章制度。
（二十一）劳动保障部门负责规范劳务派遣和劳务输出工作，指导劳务派遣、劳务输出工作中涉及劳动关系的建立、劳动争议处理、参保缴费、个人账户接续和转移的手续办理、社会保险待遇的落实等事项。
财政、工商、税务、金融等部门根据有关法律、法规和自治区政策规定，按照各自职责，依法加强对劳务派遣组织和劳务输出工作的监督检查。
Provisions for Supervision of Drug Distribution
Provisions for Supervision of Drug Distribution
(SFDA Decree No.26)
The Provisions for Supervision of Drug Distribution, adopted at the executive meeting of the State Food and Drug Administration on December 8, 2006, is hereby promulgated and shall go into effect as of May 1, 2007.
Shao Mingli
Commissioner of SFDA
January 31, 2007
Provisions for Supervision of Drug Distribution
Chapter I
Article 1 These Provisions are formulated for the purposes of strengthening drug supervision, regulating drug distribution order and ensuring drug quality in accordance with the Drug Administration Law of the People’s Republic of China (hereinafter referred to as Drug Administration Law), the Regulations for Implementation of the Drug Administration Law of the People’s Republic of China (hereinafter referred to as Regulations for Implementation of the Drug Administration Law) and the requirements of the relevant law and regulations.
Article 2 Any institutions or individuals engaged in the purchase, sales and supervision of drugs in the People’s Republic of China shall abide by the Provisions.
Article 3 Drug manufacturers, distributors and medical institutions shall be responsible for the quality of the drugs that they produce, distribute or use.
Drug manufacturers and distributors shall carry out reforms and innovations in the direction of pharmaceutical logistics provided that drug quality is assured.
Article 4 The drug regulatory departments encourage individuals and organizations to involve in the social supervision on drug distribution. Individuals or organizations have the right to report or accuse of any violation of the Provisions to the drug regulatory departments.
Chapter II Supervision on Drug Purchase and Sales by Manufacturers and Distributors
Article 5 Drug manufacturers or distributors shall be responsible for their drug purchases and sales, and liable for the purchases and sales activities of their sales staff or offices in the name of their enterprise.
Article 6 Drug manufacturers or distributors shall train their purchase and sales staff on drug related laws, regulations and professional knowledge, and establish training records including time, venue, content and trainees.
Article 7 Drug manufacturers or distributors shall strengthen the management of the sales staff and set up specific rules for their sales behaviors.
Article 8 Drug manufacturers or distributors shall not store or spot trade drugs on the premises not approved by the drug regulatory departments.
Article 9 Drug manufacturers shall sell drugs that they produce in the name of themselves, and shall not sell any drug that they produce for contract manufacturing or any drugs produced by others.
Article 10 Where a drug manufacturer or wholesaler sells drugs, it shall provide the following materials:
(1) Copies of the Drug Manufacturing Certificate or Drug Supply Certificate, stamped with the seal of the enterprise, and the business license;
(2) Copies of the approval documents for the drug to be sold, stamped with the seal of the enterprise ;
(3) For import drug sales, relevant proof documents should be provided in accordance with the related provisions of the State.
Where a drug manufacturer or wholesaler sends any of its sales staff to sell drugs, it shall, in addition to the materials prescribed in the previous paragraph of this Article, provide a copy of the authorization letter with the seal of the enterprise. The original authorization letter shall contain the authorized drugs, regions and time of validity for drug sales, indicate the identity card numbers of the sales staff, and be stamped with the enterprise seal and legal representative seal (or signature). The sales staff shall show the original authorization letter and identity card for the check by drug purchasers.
Article 11 Where a drug manufacturer or wholesaler sells drugs, it shall provide sales document indicating supplier’s name, drug name, manufacturer, batch number, quantity, price, etc.
Where a drug retailer sells drugs, it shall provide sales document indicating drug name, manufacturer, quantity, price, batch number, etc.
Article 12 Where a drug manufacturer or distributor purchases drugs, it shall request, examine and retain the relevant certificates and documents of the supplier in accordance with the requirements set forth in Article 10 of the Provisions, and request and retain sales document in accordance with the requirements set forth in Article 11 of the Provisions.
The documents retained by the drug manufacturer or distributor in accordance with the previous paragraph of this Article shall be kept till one year after the date of expiry, but not less than three years.
Article 13 Where a drug manufacturer or distributor knows or should know that any person without certificates produces or distributes drugs, it shall not provide the person with any drug.
Article 14 A drug manufacturer or distributor shall not provide premises, qualifications documents, notes, etc. as conveniences for others to distribute drugs in its own name.
Article 15 A drug manufacturer or distributor shall not spot trade drugs by means of exhibition, exposition, trade fair, commodity fair or product promotion event.
Article 16 A drug distributor shall not purchase or sell pharmaceutical preparations prepared by medical institutions.
Article 17 A drug distributor shall not change its distribution mode without approval of the drug regulatory department.
A drug distributor shall operate within the approved distribution scope in the Drug Supply Certificate.
Article 18 A drug retailer shall, pursuant to the requirements of drug classification regulations set forth by the State Food and Drug Administration, sell prescription drugs in the presence of prescriptions.
Any drug retailer selling prescription drugs or Class A non-prescription drugs shall, in the absence of its licensed pharmacists and other qualified pharmaceutical professionals, put up a public notice and stop selling prescription drugs and Class A non-prescription drugs.
Article 19 For drugs that need low-temperature or cold storage as specified in drug insert sheets, the drug manufacturer or distributor shall transport and store the drugs with low-temperature or cold storage facilities in accordance with the relevant provisions.
When finding any drug manufacturer or distributor violates the requirements in the previous paragraph of this article, the drug regulatory department shall seal up or seize the drugs concerned immediately and deal with the matter in accordance with law.
Article 20 A drug manufacturer or distributor shall not provide the public with prescription drug or Class A non-prescription drug by means of tie-in sale, offering free drugs in association with sales of drug or commodity sale, etc.
Article 21 A drug manufacturer or distributor shall not sell prescription drugs directly to the public by post or over internet.
Article 22 Any illegal purchase of drugs is prohibited.
Chapter III Supervision on Drug Purchase and Storage by Medical Institutions
Article 23 The pharmacy established by a medical institution shall have the premise, equipment, storage facilities, hygienic environment, and pharmaceutical professionals required for drug dispensing. It shall also have the drug quality control units or personnel, and establish a system for drug storage.
Article 24 Where a medical insititution purchases drugs, it shall request, examine and retain the relevant certificates, documents and notes of the supplier in accordance with the requirements set forth in Article 12 of the Provisions.
Article 25 Where a medical institution purchases drugs, it shall establish and apply an examination and acceptance system, and keep authentic and complete purchase records. Purchase records shall indicate the adopted name of the drug in China, manufacturer (for Chinese crude drug, the origin should be noted), dosage form, date of expiry, drug approval number, supplier, quantity, price and date of purchase.
Drug purchase records shall be kept till one year after the date of expiry, but not less than three years.
Article 26 A medical institution shall establish and apply a system for drug storage and maintenance, and take necessary measures to ensure drug quality, such as cold storage, protection against freeze and humidity, ventilation, moisture proof, protection from direct light and fire, and avoidance of insects and rodents.
A medical institution shall store drugs and non-drug products separately; Chinese crude drugs, prepared slices of Chinese crude drugs, pharmaceuticals, and traditional Chinese medicine preparations shall be stored separately by category.
Article 27 A medical institution or family planning technical service institution shall not directly provide drugs for patients without diagnosis or treatment.
Article 28 A medical institution shall not sell prescription drugs directly to the public by post or over internet.
Article 29 Where a medical institution purchases drugs via a centralized tendering, it shall comply with the relevant requirements of the Drug Administration Law, Regulations for Implementation of the Drug Administration Law and the Provisions.
Chapter IV Legal Liabilities
Article 30 In any of the following circumstances, the drug manufacturer or distributor shall be instructed to rectify within a time limit and given a disciplinary warning; and if the drug manufacturer or distributor fails to do so, it shall be fined not less than RMB 5,000 yuan but not more than RMB 20,000 yuan:
(1) any drug manufacturer or distributor in violation of Article 6 of the Provisions;
(2) any drug manufacturer or wholesaler in violation of the first paragraph of Article 11 of the Provisions;
(3) any drug manufacturer or distributor, in violation of Article 12 of the Provisions, failing to keep the relevant documents as required.
Article 31 Any drug manufacturer or distributor in violation of Article 7 of the Provisions shall be given a disciplinary warning and instructed to rectify within a time limit.
Article 32 In accordance with the provisions in Article 73 of the Drug Administration Law, in any of the following circumstances, the drugs illegally sold and the illegal gains therefrom shall be confiscated, and the drug manufacturer or distributor shall be fined not less than two times but not more than five times the value of the drugs illegally sold:
(1) any drug manufacturer or distributor, in violation of Article 8 of the Provisions, spot trading drugs on the premises not approved by the drug regulatory departments.
(2) any drug manufacturer in violation of Article 9 of the Provisions;
(3) any drug manufacturer or distributor in violation of Article 15 of the Provisions;
(4) any drug distributor in violation of Article 17 of the Provisions.
Article 33 Any drug manufacturer or distributor, in violation of Article 8 of the Provisions, storing drugs on the premises not approved by the drug regulatory departments，shall be punished pursuant to the provisions in Article 74 of the Regulations for Implementation of the Drug Administration Law.
Article 34 Any drug retailer in violation of the provisions in the second paragraph of Article 11 of the Provisions shall be instructed to rectify and given a disciplinary warning; and if the drug retailer fails to do so within a time limit, it shall be fined not more than RMB 500 yuan.
Article 35 Where a drug manufacturer or distributor, in violation of Article 13 of the Provisions, knows or should know that any person without certificates produces or distributes drugs, but still provide the person with drugs, they shall be given a disciplinary warning, instructed to rectify and fined not more than RMB 10,000 yuan. If the circumstances are serious, they shall be fined not less than RMB 10,000 yuan but not more than RMB 30,000 yuan.
Article 36 Drug manufacturers and distributors in violation of Article 14 of the Provisions shall be punished pursuant to the provisions in Article 82 of the Drug Administration Law.
Article 37 Where a drug distributor, in violation of Article 16 of the Provisions, purchases or sells pharmaceutical preparations dispensed by medical institutions, it shall be punished pursuant to the provisions in Article 80 of the Drug Administration Law.
Article 38 Any drug retailer in violation of the first paragraph of Article 18 of the Provisions shall be instructed to rectify within a time limit and given a disciplinary warning; if it fails to do so or the circumstances are serious, it shall be fined not more than RMB 1,000 yuan.
Where a drug retailer, in violation of the second paragraph of Article 18 of the Provisions, sells prescription drugs or Class A non-prescription drugs in absence of licensed pharmacists or other qualified pharmaceutical professionals, it shall be instructed to rectify within a time limit and given a disciplinary warning; if it fails to do so, it shall be fined not more than RMB 1,000 yuan.
Article 39 Where a drug manufacturer or wholesaler, in violation of Article 19 of the Provisions, fails to transport drugs under low-temperature or cold storage conditions as specified in insert sheets, it shall be given a disciplinary warning and instructed to rectify within a time limit; if it fails to do as instructed, it shall be fined not less than RMB 5,000 yuan but not more than RMB 20,000 yuan. Where the drugs concerned are legally proved to be counterfeit or substandard drugs, the drug manufacturer or wholesaler shall be punished in accordance with the relevant provisions of the Drug Administration Law.
Where a drug manufacturer or wholesaler, in violation of Article 19 of the Provisions, fails to store drugs under low-temperature or cold storage conditions as specified in insert sheets, it shall be punished pursuant to the provisions in Article 79 of the Drug Administration Law. Where the drugs concerned are legally proved to be counterfeit or substandard drugs, the drug manufacturer or wholesaler shall be punished in accordance with the relevant provisions of the Drug Administration Law.
Article 40 Any drug manufacturer or distributor in violation of Article 20 of the Provisions shall be instructed to rectify within a time limit and given a disciplinary warning; if the drug manufacturer or distributor fails to do so or the circumstances are serious, they shall be fined not more than two times the value of the free drugs offered, but not more than RMB 30,000 yuan.
Article 41 Any institution, in violation of Article 23 to Article 27 of the Provisions, shall be instructed to rectify within a time limit; if the circumstances are serious, it shall be announced.
Article 42 Where a drug manufacturer or distributor in violation of Article 21 of the Provisions or a medical institution in violation of Article 28 of the Provisions sells prescription drugs directly to the public by post, over internet, etc., they shall be instructed to rectify, given a disciplinary warning, and fined not more than two times the value of the drugs sold, but not more than RMB 30,000 yuan.
Article 43 Any illegal purchase of drugs, in violation of Article 22 of the Provisions, shall be punished pursuant to the provisions in Article 73 of the Drug Administration Law.
Article 44 Where a drug regulatory department or its staff that neglects its duty fails to stop or punish illegal activities that should be stopped or punished, administrative sanctions shall be imposed to the person directly in charge and other persons directly responsible. If a crime is constituted, criminal liabilities shall be investigated in accordance with law.
Chapter V Supplementary Provisions
Article 45 Spot trading of drugs in the Provisions refers to the activity that drug manufacturers, distributors or their appointed sales staff carry and sell drugs to unspecified objects on spot other than the premises approved by the drug regulatory departments.
Article 46 With respect to the supervision on the distribution of specially controlled drugs, vaccines, and military medicines, if otherwise provided by the relevant laws, regulations and provisions, they shall prevail.
Article 47 The Provisions shall come into force as of May 1, 2007. As of the date when the Provisions goes into effect, the Provisions for Supervision of Drug Distribution (Interim) (SFDA Decree No.7) implemented on August 1, 1999 shall be annulled therefrom.
